Andere Sprachen Sangamo Therapeutics, Inc.

Aktien

936386

US8006771062

SGMO

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 03.06.2024			% 5 Tage	% 1. Jan.
0,5828 ^USD	+3,26 %		-2,08 %	+7,27 %

14.05.	Transcript : Sangamo Therapeutics, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 08:30 AM
09.05.	Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sangamo: Q1 Earnings Snapshot	09.05.
Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000	09.05.
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results	09.05.
Sangamo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024	09.05.
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing	09.05.
Sangamo Therapeutics : ASGCT 2024	09.05.
Sangamo Therapeutics : Site-directed integration of large DNA sequences into endogenous sites in the human genome using engineered Modular Integrases (MINTS)	08.05.
Sangamo Therapeutics : Widespread CNS Tau Knockdown for the Potential Treatment of Alzheimer’s Disease and other Tauopathies	08.05.
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast	02.05.
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data from Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting	23.04.
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)	22.04.
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	25.03.
Sangamo Therapeutics Prices $24 Million Registered Direct Offering	22.03.
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	22.03.
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	14.03.
Sangamo: Q4 Earnings Snapshot	13.03.
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	13.03.
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs	13.03.
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023	13.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Sangamo Therapeutics, Inc.

Aktien

936386

US8006771062

SGMO

Andere Sprachen

Filter